TY - JOUR
T1 - Retinopathy of prematurity
T2 - Preferred practice patterns among pediatric ophthalmologists
AU - Fouzdar Jain, Samiksha
AU - Song, Helen H.
AU - Al-Holou, Shaza N.
AU - Morgan, Linda A.
AU - Suh, Donny W.
N1 - Funding Information:
The study was conducted at Children's Hospital and Medical Center and the University of Nebraska Medical Center.
Publisher Copyright:
© 2018 Fouzdar Jain et al.
PY - 2018/5/28
Y1 - 2018/5/28
N2 - Purpose: The treatment of retinopathy of prematurity (ROP) is not standardized and can vary significantly between providers. This study aims to determine preferred practices in treating ROP by globally surveying pediatric ophthalmologists.Methods: Between January and February 2017, an international pediatric ophthalmology interest group was invited to complete an anonymous survey of 18 questions. The main objectives were to determine the preferred first line of treatment for ROP, the preferred dosage of intravitreal bevacizumab (IVB) used, and the outcome and possible complications following bevacizumab injection. Results: Out of 101 pediatric ophthalmologists, 72 (71.8%) stated that they had direct involvement in the treatment of ROP. When presented with type 1 ROP which requires treatment, 69 ophthalmologists (68.3%) stated that they prefer laser treatment over bevacizumab, and 33 ophthalmologists (32.7%) stated they would recommend bevacizumab as a first choice. Ninety-three ophthalmologists (92.1%) reported the success of 1 laser treatment between 75% and 100%, and 35 ophthalmologists (34.7%) perceive bevacizumab to be 75%-100% successful. Half dose of adult-prescribed bevacizumab at 0.625 mg/0.05 mL was preferred by 47 of the ophthalmologists (46.5%). No cases of endophthalmitis were reported with intravitreal injection. Conclusion: Laser photoablation remains the preferred mode of treatment for ROP among surveyed ophthalmologists across the world. Though bevacizumab is currently being used, this form of treatment is not as common, primarily due to the unknown safety profile and potential long-term ramifications of the drug.
AB - Purpose: The treatment of retinopathy of prematurity (ROP) is not standardized and can vary significantly between providers. This study aims to determine preferred practices in treating ROP by globally surveying pediatric ophthalmologists.Methods: Between January and February 2017, an international pediatric ophthalmology interest group was invited to complete an anonymous survey of 18 questions. The main objectives were to determine the preferred first line of treatment for ROP, the preferred dosage of intravitreal bevacizumab (IVB) used, and the outcome and possible complications following bevacizumab injection. Results: Out of 101 pediatric ophthalmologists, 72 (71.8%) stated that they had direct involvement in the treatment of ROP. When presented with type 1 ROP which requires treatment, 69 ophthalmologists (68.3%) stated that they prefer laser treatment over bevacizumab, and 33 ophthalmologists (32.7%) stated they would recommend bevacizumab as a first choice. Ninety-three ophthalmologists (92.1%) reported the success of 1 laser treatment between 75% and 100%, and 35 ophthalmologists (34.7%) perceive bevacizumab to be 75%-100% successful. Half dose of adult-prescribed bevacizumab at 0.625 mg/0.05 mL was preferred by 47 of the ophthalmologists (46.5%). No cases of endophthalmitis were reported with intravitreal injection. Conclusion: Laser photoablation remains the preferred mode of treatment for ROP among surveyed ophthalmologists across the world. Though bevacizumab is currently being used, this form of treatment is not as common, primarily due to the unknown safety profile and potential long-term ramifications of the drug.
KW - Intravitreal bevacizumab
KW - Laser photoablation
KW - Neonatal intensive care unit
KW - Retinopathy of prematurity
UR - http://www.scopus.com/inward/record.url?scp=85047993302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047993302&partnerID=8YFLogxK
U2 - 10.2147/OPTH.S161504
DO - 10.2147/OPTH.S161504
M3 - Article
C2 - 29881255
AN - SCOPUS:85047993302
SN - 1177-5467
VL - 12
SP - 1003
EP - 1009
JO - Clinical Ophthalmology
JF - Clinical Ophthalmology
ER -